• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Announces Partnership with p-Chip Corporation to Develop Solutions for Digital Traceability of Smart Consumables

    10/23/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email

    New product line will enable secure chain-of-identity, enhanced traceability, and digital process control in pharmaceutical and clinical workflows – supporting the growing demand for individualized therapies

    RADNOR, Pa. and CHICAGO, Oct. 23, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced a collaboration agreement with p-Chip Corporation to co-develop a new generation of "Smart Consumables" by embedding p-Chip's innovative microtransponder technology into Avantor's laboratory and clinical consumables.

    Avantor. Setting science in motion to create a better world. (PRNewsfoto/Avantor)

    This partnership combines Avantor's industry leading expertise and scale with p-Chip's digital microtransponder technology platform. The collaboration will focus on engagement with joint strategic customers in life sciences, diagnostics, bio-manufacturing, and healthcare to provide solutions for digital process control that enable compliance with Chain-of-Identity ("COI") requirements.

    The Smart Consumables developed under this collaboration will provide a next-generation solution with secure and trusted digital process control for COI compliance. Consumables, such as vials, slides, cassettes, tubes and plates will be embedded with a durable p-Chip microtransponder with a unique and secure identifier. This will enable end-to-end traceability and automated process control, ensuring that critical samples and reagents are tracked and verified at every step.

    The growing demand for precision and individualized therapies is aggressively driving the need for high-fidelity sample traceability and a secure COI. This category of personalized therapeutics, including advanced cell and gene therapies, require patient samples to be securely and unambiguously identified, monitored and linked to all data throughout its end-to-end process, and to the therapeutic journey from collection to administration. By building digital identification directly into consumable labware, Smart Consumables help provide the level of tracking, authenticity verification, and compliance that these innovative treatments demand.

    "This innovation supports Avantor's mission to enable scientific breakthroughs and allows us to meet high-value customer needs in rapidly evolving areas like personalized medicine," said Corey Walker, President of Laboratory Solutions at Avantor. "Embedding digital intelligence into our consumables will deliver a new level of traceability and process control for our customers and underscores our commitment to developing proprietary and digitally enabled lab solutions."

    "Our microtransponder platform will play a pivotal role in advancing traceability and compliance in lab workflows through this collaboration," said Michael Hadjisavas, Chief Operating Officer, Life Sciences and Healthcare, p-Chip Corporation. "By equipping consumable labware with secure, unique digital identifiers, we are helping labs maintain an unbroken chain-of-identity for samples and reagents. We are confident that this not only streamlines quality control but also accelerates the digital transformation of pharmaceutical and healthcare processes – supporting better patient outcomes in the era of digital healthcare."

    About Avantor

    Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

    About p-Chip Corporation

    p-Chip Corporation is a Chicago-based technology company pioneering a new class of microtransponder tags for digital identity management in traceability and authentication of physical products and materials of industrial value chains. The p-Chip® microtransponder is a tiny silicon chip – about the size of a grain of salt – that can be embedded into or attached onto products to assign a secure, unchangeable digital identity. By creating a "digital twin" for physical items, p-Chip enables unprecedented levels of traceability, security, and supply chain visibility. p-Chip's platform is transforming how industries like healthcare, life sciences, food and automotive ensure the integrity of their products and comply with chain-of-custody requirements. For more information, visit www.p-chip.com.

    Avantor Media Contact

    Eric Van Zanten

    Head of External Communications

    Avantor

    610-529-6219

    [email protected]

    Avantor Investor Relations Contact

    Allison Hosak

    Senior Vice President, Global Communications

    Avantor

    908-329-7281

    [email protected]

    p-Chip Media Contact

    Lyda Guilfoyle

    [email protected]

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-announces-partnership-with-p-chip-corporation-to-develop-solutions-for-digital-traceability-of-smart-consumables-302592029.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    11/4/2025Outperform → Mkt Perform
    Raymond James
    10/30/2025$12.00Overweight → Equal Weight
    Barclays
    10/30/2025$12.00Overweight → Neutral
    Analyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $AVTR
    SEC Filings

    View All

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    11/10/25 5:11:45 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Avantor Inc.

    10-Q - Avantor, Inc. (0001722482) (Filer)

    10/29/25 9:01:46 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    10/29/25 6:13:10 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avantor downgraded by Raymond James

    Raymond James downgraded Avantor from Outperform to Mkt Perform

    11/4/25 7:41:39 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Barclays with a new price target

    Barclays downgraded Avantor from Overweight to Equal Weight and set a new price target of $12.00

    10/30/25 8:01:08 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Analyst with a new price target

    Analyst downgraded Avantor from Overweight to Neutral and set a new price target of $12.00

    10/30/25 8:01:08 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology

    Research & Development Council of New Jersey honors Avantor for developing a biodegradable detergent solution that advances safe, sustainable biomanufacturing RADNOR, Pa., Nov. 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the Company, in partnership with Amgen, received a 2025 Edison Patent Award from the Research & Development Council of New Jersey. The recognition was for their pioneering development of a biodegradable detergent that enables safer, more sustainable viral inactivation in biomanufacturing. Co-developed by Avantor

    11/25/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Expands Centralized Service Center Model with Opening of Boston-Area Facility

    RADNOR, Pa., Nov. 19, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its newest Centralized Service Center (CSC) serving the Greater Boston area.   The new facility in Watertown, Massachusetts, addresses the shortage of laboratory space for scientific research by enabling organizations to maximize their research footprint, accelerate discoveries, and reduce operational complexity through off-site support for essential but non-core services such as media and buffer preparation, chemical management,

    11/19/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer

    RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit

    11/10/25 8:30:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Ligner Emmanuel bought $993,125 worth of shares (87,500 units at $11.35), increasing direct ownership by 45% to 283,424 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    11/17/25 5:45:30 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP, Chief Operating Officer Blenn Mary was granted 17,391 shares (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    11/12/25 5:06:40 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Blenn Mary

    3 - Avantor, Inc. (0001722482) (Issuer)

    11/12/25 5:05:43 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Ligner Emmanuel bought $993,125 worth of shares (87,500 units at $11.35), increasing direct ownership by 45% to 283,424 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    11/17/25 5:45:30 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $1,125,000 worth of shares (100,000 units at $11.25) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/31/25 9:46:22 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $1,256,000 worth of shares (100,000 units at $12.56) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/22/25 4:15:22 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer

    RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit

    11/10/25 8:30:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Gregory T. Lucier to its Board of Directors

    Brings more than three decades of leadership experience in the life sciences industry RADNOR, Pa., Oct. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Gregory T. Lucier to its Board of Directors. Mr. Lucier brings significant experience and broad expertise across the healthcare landscape to the Avantor Board. He founded and serves as Executive Chairman and CEO of Corza Medical, a leading global manufact

    10/3/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

    RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

    11/6/24 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® Reports Third Quarter 2025 Results

    Net sales of $1.62 billion, decrease of 5%Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 millionAdjusted EBITDA of $268 million; adjusted EPS of $0.22Operating cash flow of $207 million; free cash flow of $172 millionCompany announces $500 million share repurchase authorization, reflecting confidence in cash generation and commitment to driving long-term shareholder valueRADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its t

    10/29/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Third Quarter 2025 Earnings Call on Wednesday, October 29, 2025

    RADNOR, Pa., Oct. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, October 29, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global

    10/1/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials